Abstract
As drug companies move their R&D operations out of Quebec in rapid succession, Canadian authorities are trying to sustain the region’s life sciences community. In the latest effort, the government, along with AstraZeneca and Pfizer, is committing $100 million over five years to establish the NeoMed Institute, a nonprofit research center in Montreal. NeoMed aspires to bridge the gap between basic research and early clinical studies for drug candidates by offering universities and biotech start-ups funding and services. The hope is to eventually restore some of the hundreds of R&D jobs the region has lost in the past two years. AstraZeneca and Pfizer, along with any other big pharma partners that join NeoMed, will have an option to license molecules developed there. AstraZeneca is kicking in its former neuroscience research facility, which was focused on developing small molecules, along with $5 million and intellectual property for three potential pain drugs. ...
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
